» Articles » PMID: 19957014

The Role of Steroids in the Management of Brain Metastases: a Systematic Review and Evidence-based Clinical Practice Guideline

Abstract

Question: Do steroids improve neurologic symptoms in patients with metastatic brain tumors compared to no treatment? If steroids are given, what dose should be used? Comparisons include: (1) steroid therapy versus none. (2) comparison of different doses of steroid therapy.

Target Population: These recommendations apply to adults diagnosed with brain metastases.

Recommendations: Steroid therapy versus no steroid therapy Asymptomatic brain metastases patients without mass effect Insufficient evidence exists to make a treatment recommendation for this clinical scenario. Brain metastases patients with mild symptoms related to mass effect Level 3 Corticosteroids are recommended to provide temporary symptomatic relief of symptoms related to increased intracranial pressure and edema secondary to brain metastases. It is recommended for patients who are symptomatic from metastatic disease to the brain that a starting dose of 4-8 mg/day of dexamethasone be considered. Brain metastases patients with moderate to severe symptoms related to mass effect Level 3 Corticosteroids are recommended to provide temporary symptomatic relief of symptoms related to increased intracranial pressure and edema secondary to brain metastases. If patients exhibit severe symptoms consistent with increased intracranial pressure, it is recommended that higher doses such as 16 mg/day or more be considered. Choice of Steroid Level 3 If corticosteroids are given, dexamethasone is the best drug choice given the available evidence. Duration of Corticosteroid Administration Level 3 Corticosteroids, if given, should be tapered slowly over a 2 week time period, or longer in symptomatic patients, based upon an individualized treatment regimen and a full understanding of the long-term sequelae of corticosteroid therapy. Given the very limited number of studies (two) which met the eligibility criteria for the systematic review, these are the only recommendations that can be offered based on this methodology. Please see "Discussion" and "Summary" section for additional details.

Citing Articles

Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer.

Roboubi A, Wasielewski E, Bordier S, Turlotte A, Pavaut G, Scherpereel A Ther Adv Med Oncol. 2025; 17:17588359251318160.

PMID: 39935765 PMC: 11811968. DOI: 10.1177/17588359251318160.


Palliative patients who may benefit from intranasal delivery of symptomatic drugs: a two-center observational study evaluated the administration of morphine and dexamethasone in Polish hospices.

Ingielewicz A, Brunka Z, Szczupak M, Szymczak R Support Care Cancer. 2025; 33(2):140.

PMID: 39893351 PMC: 11787208. DOI: 10.1007/s00520-025-09189-z.


[Clinical Practice Guidelines for the Management of Brain Metastases from 
Non-small Cell Lung Cancer with Actionable Gene Alterations in China (2025 Edition)].

Zhongguo Fei Ai Za Zhi. 2025; 28(1):1-21.

PMID: 39763097 PMC: 11848629. DOI: 10.3779/j.issn.1009-3419.2024.102.42.


Brain tumor-related epilepsy: an overview on neuropsychological, behavioral, and quality of life issues and assessment methodology.

Maschio M, Perversi F, Maialetti A Front Neurol. 2024; 15:1480900.

PMID: 39722690 PMC: 11668670. DOI: 10.3389/fneur.2024.1480900.


Radiotherapy in patients with brain metastases with and without concomitant immunotherapy: comparison of patient outcome and neurotoxicity.

Elyan N, Schwenkenbecher P, Grote-Levi L, Becker J, Merten R, Christiansen H Discov Oncol. 2024; 15(1):656.

PMID: 39546075 PMC: 11568079. DOI: 10.1007/s12672-024-01560-6.


References
1.
Robinson P, Kalkanis S, Linskey M, Santaguida P . Methodology used to develop the AANS/CNS management of brain metastases evidence-based clinical practice parameter guidelines. J Neurooncol. 2009; 96(1):11-6. PMC: 2808528. DOI: 10.1007/s11060-009-0059-2. View

2.
Andersen C, Astrup J, Gyldensted C . Quantitation of peritumoural oedema and the effect of steroids using NMR-relaxation time imaging and blood-brain barrier analysis. Acta Neurochir Suppl (Wien). 1994; 60:413-5. DOI: 10.1007/978-3-7091-9334-1_112. View

3.
Weissman D, Janjan N, Erickson B, Wilson F, Greenberg M, Ritch P . Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases. J Neurooncol. 1991; 11(3):235-9. DOI: 10.1007/BF00165531. View

4.
Borgelt B, Gelber R, Kramer S, BRADY L, Chang C, Davis L . The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980; 6(1):1-9. DOI: 10.1016/0360-3016(80)90195-9. View

5.
Vecht C, Hovestadt A, Verbiest H, van Vliet J, van Putten W . Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology. 1994; 44(4):675-80. DOI: 10.1212/wnl.44.4.675. View